schizophrenia

April 25, 2019

Immune ‘pruning’ in schizophrenia

Ariel Deutch and colleagues have discovered that overactive brain immune cells during adolescence may contribute to schizophrenia.

By Bill Snyder
Researchers who helped find high-risk genes for schizophrenia included, from left, Quan Wang, PhD, Bingshan Li, PhD, Nancy Cox, PhD, Rui Chen, PhD, Xue Zhong, PhD, Qiang Wei, PhD, and James Sutcliffe, PhD.
April 18, 2019

Researchers find high-risk genes for schizophrenia

Using a unique computational framework they developed, a team of scientist cyber-sleuths in the Vanderbilt University Department of Molecular Physiology and Biophysics and the Vanderbilt Genetics Institute (VGI) has identified 104 high-risk genes for schizophrenia.

By Bill Snyder
March 28, 2019

Treatment resistance of mental disorders studied

With the aid of a four-year, $3.4 million grant from the National Institute of Mental Health, researchers at Vanderbilt University Medical Center and Massachusetts General Hospital (MGH) will apply new techniques to investigate treatment resistance of two devastating mental disorders — major depressive disorder, which befalls 15 percent of people at some point in their lives, and schizophrenia, which affects approximately 1 percent.

By Paul Govern
October 1, 2018

Cytokine-cognition connection

Targeting the immune system may provide a new avenue for therapeutic intervention in psychiatric diseases characterized by motivational and cognitive deficits.

By Laura Daniel
June 14, 2018

Shared genetics may shape treatment options for certain brain disorders

Symptoms of schizophrenia and bipolar disorder, including psychosis, depression and manic behavior, have both shared and distinguishing genetic factors, an international consortium led by researchers from Vanderbilt University and Virginia Commonwealth University is reporting.

By Bill Snyder
March 9, 2018

Brain connections in schizophrenia

Brain imaging studies have implicated the connection between two brain regions in the pathophysiology of schizophrenia.

By Leigh MacMillan
January 8, 2018

Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment

Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.
By Bill Snyder
August 7, 2017

Vanderbilt begins Phase 1 trials of new Alzheimer’s drug

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
By Bill Snyder
December 27, 2016

Investigational new drug for Alzheimer’s scheduled for first study in humans

Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.
By Craig Boerner
September 15, 2016

Researchers eye potential schizophrenia ‘switch’

Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice.
By Bill Snyder
August 15, 2016

Foundation’s support speeds search for new schizophrenia drugs at Vanderbilt

Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.
By Bill Snyder
March 21, 2016

Putting schizophrenia to bed

A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation.
By VUMC News and Communications
August 21, 2015

Brain circuitry in psychosis

Functional magnetic resonance imaging has revealed faulty circuits between the thalamus – a central hub of brain activity – and other brain regions.
By Leigh MacMillan
1 2 3 4